On December 15, 2022, Saili Medical announced that the company's controlling shareholder, Saihai Science and Technology, intends to transfer its 14 million shares of the company (accounting for 6.88% of the company's total share capital) to the Angze Taiying VI Private Securities Investment Fund managed by Shanghai Angze Private Equity Fund Management Co. Ltd. at a transfer price of RMB 11.78/share, with a total transfer price (including tax)*** counting 165 million yuan.
Data shows that Sealy Medical has been y committed to the development of the IVD field over the years, in recent years, while the development of the traditional IVD-based, self-developed software development of the SPD business and to promote the hierarchical diagnosis of government hospitals and tripartite cooperation in the regional testing centers and other businesses, Sealy Medical by virtue of a number of synergistic development of the business continues to digitalization, the development of intelligent health care industry transformation.
For the transfer, Saihai Technology said the transfer is aimed at supplementing the company's cash flow and reduce the pledge and other financing debt, the operating conditions of the Saili Medical will not have any impact, Shanghai Angze Private Equity Fund said that due to the investment needs of the listed companies to increase the number of shares.
According to the relevant private equity platform information, Shanghai Angze Private Equity Fund Management Co., Ltd. was founded in 2015, is a scale of 1-2 billion private equity institutions. Angze investment is located in the environment of China's economic structure transformation and upgrading, seeking high growth opportunities in emerging industries and advantageous enterprises. Through the pursuit of beta, it enables the right asset to get the right price, and the right price brings the right supply and demand, thus optimizing the strategic allocation. The private equity funds *** 29, of which the Angser Chase I nearly one year return reached 89.32% far more than the broader market and peer private equity funds.
An investment banker said, the major shareholders choose to transfer part of the equity agreement, often hoping to introduce more resources for the company to achieve high-quality development. Shanghai Angze private equity fund at this time, to a certain extent, showing its optimism about the current market and the company's development prospects, the two sides are expected to stimulate the integration of resources listed companies to greater development of vitality, I believe that the equity investment in the Seri Medical will bring new value to the company's main business.
The private equity investment in Saili Medical also proves that the market is optimistic about the company in the long term and recognizes the development potential of the company's main business. It is worth noting that, in terms of business operations, Saili Medical's recent recovery of accounts receivable has also further strengthened the company's capital recovery more to promote the subsequent development of the enterprise.
On the same day, Saili Medical released a progress announcement of accounts receivable, according to the announcement in July 2022, the company **** received 37.16 million yuan of accounts receivable from Xuzhou Municipal Central Hospital, and in October 2022 and Xuzhou Municipal Central Hospital to reach a settlement of accounts receivable program, the two sides agreed to 20 December 2022, Xuzhou Municipal Central Hospital to the company to pay the accounts receivable of 22,790,000 yuan. million yuan. In addition to this, the company has also increased a number of accounts receivable collection effect is remarkable, for the company's operations, especially in the net profit level of the growth of a huge impact, the cumulative amount of future recovery is expected to be more than 100 million yuan, but also will make the company's net profit in 2022 increased by 24,980,000 yuan, a significant increase in the company's funds back and cash reserves, to its assets, cash and profit position to bring improvement.
According to the periodic report of Saili Medical, Saili Medical has been focusing on realizing the national layout of "Intensification of Medical Testing (IVD) and Lean of Medical Consumables (SPD)" through investment since it was listed on the stock market. Through "investment+cooperation", the company introduces foreign advanced products and extends the industrial chain, and is committed to becoming a supplier of intelligent medical system construction based on "Internet of Things, Artificial Intelligence, and Medical Big Data", and is also actively laying out its digital transformation. Seri Medical as China's medical digital transformation leader, a number of its business to the intelligent digital transformation to the regional testing center, for example, according to public information to understand the Seri Medical District Inspection Center through the digital information cloud platform to achieve all levels of hospitals, resources **** enjoy superimposed on the company's own medical consumables lean (SPD) services can really do for the hospitals to save management costs and reduce the consumption of medical resources. The purpose is to save the management cost and reduce the consumption of medical resources for the hospitals.
At the same time, the company's digital layout around the smart hospital is also commendable. Saili medical through the intelligent management, intelligent medical, intelligent service three major directions of the modern intelligent hospital digital transformation, combined with DRG / DIP, intelligent home hospital and chronic disease remote intelligent management and other aspects of the Saili medical gradually perfect in the intelligent hospital digital layout and transformation at the same time also greatly release the pressure of hospitals and patients. Through the recovery of accounts receivable, the company's operations will also be improved, with sufficient cash flow layout deeper digital transformation.
According to GlobalMarketInsights, the market size of digital healthcare will reach $379 billion by 2024. At present, major pharmaceutical giants such as Novartis, Takeda, GSK and Roche pharmaceutical giants, Danaher, Roche Diagnostics and other diagnostic companies have entered the layout of digital transformation. As a one-stop solution service provider for intelligent medical construction under digital transformation, CELI Healthcare firmly adheres to the development strategy of "dual-main business", improves the ecosystem, and constructs an intelligent medical system based on "Internet of Things + Artificial Intelligence + Medical Big Data". The new height of the field, and constantly to digitalization, intelligent transformation layout.